Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

International PBM Deals? South Africa First

Executive Summary

Recent international PBM deals.

PBM dealmaking is still basically a US-based affair, as the rather short list of international PBM deals make clear. But the overwhelming favorite PBM country outside of the US is South Africa, the most accessible market for businesses which make money by controlling drug costs. South Africa’s health care market is private, as advanced as many Western countries’, and is experiencing cost containment pressures similar to those in the US that have contributed to PBMs’ successes. These cost containment pressures include political heat, in the form of a proposed national health insurance system with an essential drug list, and encouragement (by the World Health Organization, among others) to provide better care for children and the underprivileged—which will mean increased drug spending and therefore a sharper eye on cost control.

Recent International PBM deals

Date Deal

11/95 SmithKline enters South African managed care market, buying Total Support Management (PBM & mail order pharmacy)

11/95 SmithKline and Drougerias Americana form an Argentinean PBM joint venture, Diversified Sistemas de Salud

5/95 Lilly & Glaxo form South African PBM JV, buying PBM & claims processor Medikredit

5/95 Lilly buys Canadian PBM and claims processor, RxPlus

2/95 Medco & Cider Sante form French PBM, Coordination Medical et Pharmaceutique

SOURCE:Windhover’s Health Care Strategist

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

IV000063

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel